Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development

Raggi, Paolo; Baldassarre, Damiano; Day, S; Groot, Eric de; Fayad, Zahi A.

doi:10.1016/j.atherosclerosis.2016.06.028

Cited by 12 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 High spatial-resolution imaging of the carotid vessels is readily feasible, with accurate, reproducible measurements of carotid plaque thickness, volume and area derived from black-blood imaging sequences.…”

Section: Carotid Imagingmentioning

confidence: 99%

The future of imaging in cardiovascular disease intervention trials: 2017 and beyond

Doris

Dweck²,

Fayad

2016

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of Review As our understanding of cardiovascular disease has advanced over the past decades, multiple novel treatment strategies have been developed with the hope of reducing the global morbidity and mortality associated with this condition. Large-scale trials to test such novel therapies using clinical end-points are expensive, leading to interest in phase 2 clinical trials with imaging-derived outcome measures. Recent Findings Non-invasive imaging techniques that assess changes in both atherosclerotic disease burden and plaque composition in response to therapy are well established. With the advent of molecular techniques and hybrid imaging, we now have the ability to assess disease activity alongside these standard anatomic assessments. This multi-faceted approach has the potential to provide a more comprehensive assessment of the actions and efficacy of novel therapies in the carotids, aorta, and coronary arteries. Summary This review will examine how advanced non-invasive imaging strategies have been used to investigate drug efficacy in intervention trials to date, and crucially how these approaches are set to evolve and play a central role in developing the next generation of atherosclerotic medication.

show abstract

Section: Carotid Imagingmentioning

confidence: 99%

The future of imaging in cardiovascular disease intervention trials: 2017 and beyond

Doris

Dweck²,

Fayad

2016

Current Opinion in Lipidology

View full text Add to dashboard Cite

show abstract

“…The joint ESC Guidelines suggested that early diagnosis of high-risk patients could be equally effective as preventing new cases, leading to potential cost-savings, and consequently encouraged research regarding risk assessment by non-or minimally invasive imaging techniques [3]. Techniques such as multi-detector CT [4,5], intravascular ultrasound [6,7], MRI [8,9], or Optical Coherence Tomography [10] are extensively being investigated for the assessment of morphological or structural characteristics of atherosclerotic lesions. Among the molecular imaging modalities, which can reveal specific biological aspects of atherosclerotic plaques, positron emission tomography/computed tomography (PET/CT) is one of the preferred techniques in clinic [11].…”

Section: Introductionmentioning

confidence: 99%

Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging

Bridoux

Neyt²,

Debie

et al. 2020

Molecules

View full text Add to dashboard Cite

Since atherosclerotic plaques are small and sparse, their non-invasive detection via PET imaging requires both highly specific radiotracers as well as imaging systems with high sensitivity and resolution. This study aimed to assess the targeting and biodistribution of a novel fluorine-18 anti-VCAM-1 Nanobody (Nb), and to investigate whether sub-millimetre resolution PET imaging could improve detectability of plaques in mice. The anti-VCAM-1 Nb functionalised with the novel restrained complexing agent (RESCA) chelator was labelled with [18F]AlF with a high radiochemical yield (>75%) and radiochemical purity (>99%). Subsequently, [18F]AlF(RESCA)-cAbVCAM1-5 was injected in ApoE−/− mice, or co-injected with excess of unlabelled Nb (control group). Mice were imaged sequentially using a cross-over design on two different commercially available PET/CT systems and finally sacrificed for ex vivo analysis. Both the PET/CT images and ex vivo data showed specific uptake of [18F]AlF(RESCA)-cAbVCAM1-5 in atherosclerotic lesions. Non-specific bone uptake was also noticeable, most probably due to in vivo defluorination. Image analysis yielded higher target-to-heart and target-to-brain ratios with the β-CUBE (MOLECUBES) PET scanner, demonstrating that preclinical detection of atherosclerotic lesions could be improved using the latest PET technology.

show abstract

“…Thus, timely and precise diagnosis and effective treatment are essential to delay the progression of the disease and to improve the survival rate. In comparison with other diagnostic methods, such as computed tomography (CT), ultrasonic imaging, and positron emission computed tomography (PET), magnetic resonance imaging (MRI) is widely used in clinical for its advantages of no invasion, no radiation and high soft tissue contrast in imaging [4,5]. Although the contrast agents such as iron and gadolinium agent increase the imaging effectiveness [6], MRI is still difficult to distinguish between small abnormal and normal tissues.…”

Section: Introductionmentioning

confidence: 99%

VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

Zhang

Zhou

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Mortality attributable to atherosclerosis can be reduced significantly with timely diagnosis and treatment. It is meaningful to find a proper way to diagnose and prevent the progression of atherosclerosis. Vascular cell adhesion molecule-1 (VCAM-1) expressed by endothelial cells is a prominent marker of atherosclerotic plaques. There are a number of researches on VCAM-1 based probes for targeted imaging, but rarely on a system with both targeting and drug delivery. Here, we report a novel magnetic mesoporous silicon nanoparticle that is capable of drug delivery and targeting at atherosclerosis plaque. The nanoparticles were constructed using incorporated FITC (fluorescein isothiocyanate) and VHPKQHR peptide into Fe 3 O 4 @SiO 2 (FITC-VHP-Fe 3 O 4 @SiO 2). The FITC-VHP-Fe 3 O 4 @SiO 2 nanoparticles showed great morphological characteristics, superior targeting ability, low toxicity and good biocompatibility in vitro and in vivo. The in vivo experiments showed that FITC-VHP-Fe 3 O 4 @SiO 2 is a superior contrast agent of magnetic resonance imaging (MRI) for diagnosis of atherosclerosis plaques.

show abstract

Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development

Cited by 12 publications

References 55 publications

The future of imaging in cardiovascular disease intervention trials: 2017 and beyond

The future of imaging in cardiovascular disease intervention trials: 2017 and beyond

Improved Detection of Molecular Markers of Atherosclerotic Plaques Using Sub-Millimeter PET Imaging

VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

Contact Info

Product

Resources

About